Clinically validated VHH antibodies that can be readily assembled to create well differentiated next generation biotherapeutics.
Small, Stable & Robust
VHH antibodies offer advantages in the development of many highly efficacious and fast growing new biotherapeutic drugs.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.